{"nctId":"NCT01089647","briefTitle":"Montelukast and Inhaled Nasal Steroid Tx in Adult Obstructive Sleep Apnea (OSA)","startDateStruct":{"date":"2010-09"},"conditions":["Obstructive Sleep Apnea"],"count":34,"armGroups":[{"label":"budesonide and montelukast","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: budesonide and montelukast"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"budesonide and montelukast","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age 18 - 100 years\n* RDI between 5 - 15\n* all races\n* both sexes\n\nExclusion Criteria:\n\n* craniofacial, syndromic, neurological abnormalities\n* current or previous use of Singular, Rhinocort within last 6 months\n* acute upper respiratory infections\n* recent nasal trauma, nasal surgery, nasal septum perforation\n* known immunodeficiency or under going immunosuppressant therapy\n* current therapy with drugs that interact with Montelukast or Budesonide","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With a Decrease in the Number of Apnea and/or Hypopnea Events to <5 Per Hour of Sleep","description":"by decreasing nasal congestion, we hope to decrease the number of respiratory events per hour of sleep back to the normal range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["nosebleed","lower leg swelling"]}}}